Genomic and biological panoramas of non-muscle actinopathies - Di Donato, Nataliya; NMA Consortium; Thom, Andrew; Rump, Andreas; Greve, Johannes N.; Kropp, Marcus; Cadiñanos, Juan; Calabro, Salvatore; Cathey, Sara; Chung, Brian; Cope, Heidi; Costales, Maria; et al. (medRxiv, 2024)
Background Cytoskeletal non-muscle actin isoforms are the most abundant intracellular proteins and extensively interact with other molecules. Biological consequences and genotype-phenotype correlations of the variants in genes encoding these isoforms, ACTB and ACTG1, are not delineated.Methods Clinical data analysis from 290 individuals with pathogenic ACTB/ACTG1 variants; characterization of patient cells, mutant proteins, patient-derived iPSC-based models and mutant mice.Results We show that ACTB and ACTG1 variants have distinct clinical profiles. ACTB nonsense, frameshift and missense variants that lead to rapid protein degradation result in milder phenotypes. Heterozygous Actb knockout causes altered neuronal cell morphology and abnormal expression of actin-related genes in newborn mouse brains. Truncating ACTG1 variants are likely to be non-pathogenic, but chromosomal deletions encompassing ACTG1 and flanking genes may result in susceptibility to neurodevelopmental phenotypes. Subsets of disease-causing ACTB missense variants (MVs) result in more severe Type 1 Baraitser-Winter Cerebrofrontofacial (BWCFF1) or Deafness Dystonia syndromes. Pathogenic ACTG1 MVs cause BWCFF2 or isolated hearing loss. These amino acid substitutions are associated with dramatically dysregulated actin polymerization and depolymerization dynamics and, in induced pluripotent stem cells (iPSC) derived models, lead to neuronal migration defects. A significant subset of MVs result in disorders that cannot yet be classified into recognizable groups.Conclusions ACTB or ACTG1 variants and result in minimum eight mechanistically diverse non-muscle actinopathies. These results will improve their diagnosis and management, and pave the way for new treatment strategies. This study reflects the scale of collaborative clinical studies and multi-modal mechanistic studies required to dissect rare allelic disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNDD received grant support from Deutsche Forschungsgemeischaft (DFG) (DI 2170/3.1 and DI 2170/5.1) and Else-Kroener-Fresenius Stiftung (2020_EKES.04). NDD and DJM are supported through the European Union Horizon 2020 research and innovation program under the EJP RD COFUND EJP N 825575 with support from the German Federal Ministry of Education and Research under Grant Agreements 01GM1922A and 01GM1922B, respectively. DJM acknowledges grant support from: Deutsche Forschungsgemeinschaft (DFG) (MA1081/23.1, MA1081/28.1), the Cluster of Excellence RESIST (EXC 2155; DFG Project ID: 39087428.B11). ASW acknowledges grant support from: Medical Research Council project grant MR/T016809/1; Medical Research Council-National Institute for Health and Care Research rare disease research platform MR/Y008340/1; and Kidneys for Life pump priming grant 2017. SB acknowledges grant support from the NIHR Manchester Biomedical Research Centre (NIHR203308). SB, ASW, and AT acknowledge support from the Davies family for grant support in the form of Marsh Studentship to the University of Manchester. SB and SC acknowledge support from the Great Ormond Street Hospital Charity research grant V4621.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB the TU Dresden and Ethics committee/IRB of the Central Manchester gave ethical approval for this work (EK-127032017, BO-EK-341062021 and (02/CM/238). All patients ID were created specifically for this manuscript and are not known to anyone outside of teh research group.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes